Miguel Bronchud, Veteran Cancer Clinician, Researcher, Co-Founder and ex Advisory Board at Regenerative Medicine Solutions, shared on LinkedIn:
“Mapping Ecotypes in Cancers: Multiple myelomas differ from each other because of different ‘tumor microenvironment ecotypes‘? Mapping Prognosis?
Researchers at MD Anderson (Texas) have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The newly published findings provide insights that may explain why patients with similar diagnoses often have differences in disease progression, treatment response, and outcomes.
The study, published in Blood, was co-led by Robert Orlowski, MD, Professor of Lymphoma/Myeloma and Experimental Therapeutics at The University of Texas MD Anderson Cancer Center; and Linghua Wang, MD, Professor of Genomic Medicine, Executive Director and Head of the Center for Cellular Language Intelligence, Associate Member of the James P. Allison Institute, and focus area co-lead with the Institute for Data Science in Oncology at MD Anderson.
Title: Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma
Authors: Minghao Dang, Luz Yurany Moreno Rueda, Maria Jose Acevedo Calado, Hima Bansal, David Alejandro Berrios Nolasco, Amishi U Vora, Jonathan D Mejia, Mei Huang, Wei Tan, Li Qin, Yunhe Liu, Yang Liu, David E. Mery, Yan Cheng, Fenghuang Zhan, John D. Shaughnessy, Qing Yi, Pei Lin, Mahmoud R. Gaballa, Oren Pasvolsky, Hans C. Lee, Sheeba K. Thomas, Donna M Weber, Krina K. Patel, Melody R Becnel, Jing Christine Ye, Isere Kuiatse, Elisabet E Manasanch, Linghua Wang, Robert Z. OrlowskiCorresponding
Read The Full Article
Molecular delineation of five distinct tumor microenvironment ecotypes in the bone marrows of patients with plasma cell disorders provides a new framework to understand the critical role of the host immune system in the biology of these diseases.
- Five reproducible TME ecotypes define coordinated cellular and molecular programs across the myeloma disease spectrum.
- Ecotype classification reveals clinical heterogeneity beyond disease stage and may guide patient risk stratification and immunotherapy.
Multiple myeloma progresses from precursor states to active disease, and studying tumor microenvironment (TME) evolution across these stages is key to understanding immune dysregulation and therapeutic resistance.
Researchers integrated paired single-cell RNA, T-, and B-cell receptor sequencing data from bone marrow samples of 235 patients spanning the disease spectrum. This dataset revealed dynamic changes in the abundance and functional states of diverse immune populations, including T-, natural killer, B-, and myeloid cells.
Using non-negative factorization of cell-subset composition, these researchers from the MD Anderson in Houston, identified five reproducible TME subtypes, or “ecotypes,” defined by coordinated cellular architectures.
University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Corresponding Author; email: rorlowski@mdanderson.org.”
Other articles about Multiple Myeloma on OncoDaily.